Curated News
By: NewsRamp Editorial Staff
June 24, 2026

Ottobock Appoints Dr. Katarzyna Mazur-Hofsaess to Management Board

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Ottobock gains a proven MedTech leader from Fresenius and Zimmer Biomet, strengthening its competitive edge.
  • Dr. Katarzyna Mazur-Hofsaess replaces Stefan Heidenreich on Ottobock's Management Board after his five-year term ended.
  • Ottobock's new board member brings expertise to improve mobility solutions for people with limited movement.
  • Dr. Mazur-Hofsaess is a physician and former CEO, with experience at Fresenius and Smith & Nephew.

Impact - Why it Matters

This news matters because a change in leadership at a major MedTech company like Ottobock can influence the direction of innovation in prosthetics, orthotics, and exoskeletons. Dr. Mazur-Hofsaess's background in international medical technology and healthcare may bring fresh perspectives that could accelerate the development of advanced mobility solutions, directly impacting patients with limited mobility. Investors and industry watchers should also note the strategic implications for Ottobock's growth and market position, especially as the company continues to digitalize the industry and expand its global footprint.

Summary

Ottobock SE & Co. KGaA, a global leader in medical technology, has announced a significant change to its Management Board. Dr. Katarzyna Mazur-Hofsaess has been appointed as a new member, effective June 22, 2026, succeeding Stefan Heidenreich whose five-year term has ended. Professor Hans Georg Nader, Chairman of the Management Board, praised Dr. Mazur-Hofsaess as a proven expert in international medical technology and healthcare, highlighting her medical background as a valuable addition. Dr. Mazur-Hofsaess brings extensive experience from her roles at Fresenius Medical Care, Zimmer Biomet, Abbott Diagnostics, and Roche Polska, and currently serves as a non-executive Director at Smith & Nephew. She is a physician by training, holding a doctorate from the Medical University of Gdansk, and has completed management studies at the Warsaw School of Economics and the University of Minnesota.

Stefan Heidenreich, who served as Deputy Chairman, played a key role in Ottobock's strategic development and transition to a listed company. Ottobock expressed gratitude for his contributions. The announcement was made via NEWMEDIAWIRE, with the full release available on www.newmediawire.com. Ottobock, founded in 1919, operates in 45 countries with nearly 9,300 employees and over 420 patient care centers worldwide. The company specializes in prosthetics, neuro-orthotics, and exoskeletons, holding more than 2,600 patents and patent applications. Known for its strong R&D focus and partnership with the Paralympic Games since 1988, Ottobock is dedicated to improving mobility and quality of life for people with limited mobility.

This leadership transition underscores Ottobock's commitment to innovation and global expansion. Dr. Mazur-Hofsaess's appointment is expected to further strengthen the company's position in the MedTech industry, leveraging her expertise in healthcare and medical technology to drive strategic initiatives. The change comes at a pivotal time as Ottobock continues to advance human bionics and digitalization in the sector.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Ottobock Appoints Dr. Katarzyna Mazur-Hofsaess to Management Board

blockchain registration record for this content.